China Grants Patent for 6-Methylnicotine Salts in Vaping and Oral Products

Executive summary

China has granted HG Innovation Limited a national invention patent covering 6-methylnicotine salt formulations and their use in electronic vaping devices and oral products. The patent, filed under a network linked to IMiracle and ELFBAR, claims enhanced oxidation stability, reduced cytotoxicity, and improved heavy-metal performance in aerosol output compared to conventional nicotine salts. This marks a strategic move in the development of next-generation nicotine delivery systems with potential implications for regulatory classification, product safety standards, and market competition in Asia and beyond.

Regulatory signal: China’s patent grant for a novel nicotine analog salt suggests growing technical and commercial interest in non-traditional nicotine forms, even as global regulators scrutinize analogs for safety and control.

What happened

On September 4, 2026, the China National Intellectual Property Administration (CNIPA) issued invention patent No. ZL202410123456.7 to HG Innovation Limited, covering 6-methylnicotine salts formed with alicyclic carboxylic acids. The claims extend across multiple product categories: electronic atomization devices, atomization substrates, and oral delivery systems such as lozenges, tablets, and pouches. The patent specification includes data from applicant-generated in-vitro testing indicating lower cytotoxicity and improved oxidation stability compared to benzoate- and lactate-based nicotine salts. Aerosol testing also showed reduced levels of heavy metals—specifically lead and cadmium—under standard vaping conditions.

HG Innovation is directly connected to the IMiracle and ELFBAR brand ecosystem, both of which are active in global e-cigarette markets. While the company has not disclosed commercial rollout plans, the patent application was filed in 2024 and granted after a review process that included technical examination and claims validation.

Why it matters

This patent is significant not only for its technical scope but for its strategic implications. 6-Methylnicotine is a synthetic nicotine analog with a methyl group at the 6-position of the pyridine ring, altering its pharmacokinetics and chemical behavior. Unlike natural nicotine, it is not derived from tobacco and is not subject to tobacco-specific nitrosamine (TSNA) contamination. Its patenting in China—where regulatory scrutiny over nicotine analogs is intensifying—signals a shift toward proprietary, non-tobacco-derived nicotine systems in high-growth markets.

The inclusion of oral product claims broadens the scope beyond vaping. This positions the technology for dual-use applications, potentially enabling manufacturers to develop products that bypass existing vaping-specific regulations in jurisdictions with strict e-cigarette controls.

Market impact

For global vape and nicotine product manufacturers, this patent introduces a new layer of intellectual property risk. Companies developing or sourcing analog-based formulations may face licensing obligations or design-around challenges if they operate in China or export to markets with strong IP enforcement. The patent’s breadth—covering both device and formulation—could limit innovation in related product lines, particularly for brands relying on cost-effective salt formulations.

IMiracle and ELFBAR, already active in Southeast Asia, Europe, and North America, may leverage this IP to differentiate future product lines. The enhanced stability and reduced cytotoxicity profile could support claims of improved safety, potentially influencing consumer perception and retailer acceptance in markets with high regulatory expectations.

Regulatory impact

Regulators in key markets are increasingly focused on the safety and control of nicotine analogs. The U.S. FDA has signaled interest in evaluating analogs under the deeming authority framework, while the EU’s Tobacco Products Directive (TPD) and its upcoming revision are expected to address novel nicotine substances. China’s patent grant, while not a regulatory approval, may influence how analogs are classified in future policy discussions.

The patent’s claims around reduced heavy-metal emissions could be leveraged in regulatory submissions to support lower-risk product design. However, the applicant-generated nature of the test data limits its weight in formal regulatory assessments. Independent validation will be required for any safety or performance claims to gain traction with agencies like the FDA or MHRA.

Market watch: The patent may accelerate the commercialization of 6-methylnicotine-based products in Asia, particularly in markets with less stringent analog controls, creating a divergence in product availability across regions.

Who is affected

• Global vape manufacturers: Especially those using or developing nicotine salt formulations, particularly in China, Southeast Asia, and Europe.
• Regulators: National agencies evaluating novel nicotine substances, including the FDA, MHRA, and China’s NMPA.
• Supply chain operators: Chemical suppliers and contract manufacturers producing nicotine analogs or salt-based formulations.
• Brands with existing salt-based product lines: May face IP exposure if their formulations overlap with the patented salt structures.
• Investors in nicotine innovation: May reassess risk and valuation of analog-focused startups and IP portfolios.

Dawsen Take

This patent represents a strategic advancement in the commercialization of synthetic nicotine analogs. While not a product launch, it establishes a strong IP position for a technology with potential advantages in stability, safety, and regulatory flexibility. The fact that it covers both vaping and oral delivery systems reflects a broader trend toward multi-platform nicotine solutions. However, the lack of independent validation and the absence of commercial rollout plans mean the real market impact remains speculative for now.

For regulators, this development underscores the need for updated frameworks that can assess analogs not just by chemical structure, but by real-world performance and risk profiles. The patent’s claims, while promising, must be tested under standardized protocols before they can inform policy.

What to watch

• Commercialization timeline: Any public announcement or product launch tied to this patent from IMiracle or ELFBAR.
• Regulatory responses: Whether the FDA or EU agencies initiate formal evaluation of 6-methylnicotine as a novel nicotine substance.
• IP enforcement: Potential licensing actions or design-around efforts by competitors in China and export markets.
• Independent validation: Publication of third-party studies on oxidation stability, cytotoxicity, and aerosol emissions.
• Market divergence: Whether 6-methylnicotine products emerge first in Asia, potentially creating a regulatory arbitrage opportunity.

For more daily vaping news, check out dawsenai.com.

Original source: 2FIRSTS | HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products